HOME >> BIOLOGY >> NEWS
Blasting antibodies with lasers provides direct way of measuring their flexibilities

A group of scientists at The Scripps Research Institute (TSRI) and San Diego Supercomputer Center at the University of California at San Diego (UCSD) have used a powerful laser in combination with innovative quantum mechanical computations to measure the flexibility of mouse antibodies.

The new technique, described in an upcoming issue of the journal Proceedings of the National Academy of Sciences, is significant because protein flexibility is believed to play an important role in antibody-antigen recognition, one of the fundamental events in the human immune system.

"This is the first time anybody has ever gone into a protein and experimentally measured the frequency of protein vibrations in response to an applied force," says Floyd Romesberg, assistant professor in the Department of Chemistry at The Scripps Research Institute, who led the study.

"Our results show that the motions of the antibody-antigen complexes can range over four orders of magnitude, from tens of femtoseconds to hundreds of picoseconds," says co-author Kim K. Baldridge, Ph.D., director of Integrative Computational Sciences at the San Diego Supercomputer Center and an adjunct professor of Chemistry at UCSD. "This is evidence of a general mechanism of antigen-antibody interactions--which range from rigid to flexible," she adds.

Flexibility of Proteins

Protein flexibility is an important concept in biology because of its role in protein-protein and protein-ligand recognition. One of the longest running debates in molecular recognition is how proteins recognize and bind to other molecules--whether it resembles putting a key into a lock (the lock and key model) or catching a baseball in a catcher's mitt (the induced fit model).

There are lots of ideas about mechanisms of antigen recognition postulated in the literature, but what the debate comes down to is really a question of flexibility. How flexible are proteins?

Unfortunately, fle
'"/>

Contact: Keith McKeown
kmckeown@scripps.edu
858-784-8134
Scripps Research Institute
17-Dec-2002


Page: 1 2 3

Related biology news :

1. Researchers find clues about how antibodies specialize
2. Second generation targeted antibodies - Its all in the binding
3. Anti-interferon beta antibodies in MS care: A consensus
4. Researchers show autoantibodies occur before lupus in New England Journal of Medicine
5. Programmable antibodies-- hybrid cancer therapy described by scientists at Scripps
6. Bodys own antibodies may drive new strains of HIV
7. Growing human antibodies in algae
8. Ozone produced by antibodies during bacterial killing and in inflammation
9. Artificial antibodies created by new molecular imprinting process
10. Human antibodies against spores found by researchers suggest new tool to detect and treat anthrax
11. Scientists at The Scripps Research Institute discover a previously unknown role for antibodies

Post Your Comments:
(Date:5/6/2015)... 6, 2015 LifeBEAM, a developer of bio-sensing ... announced today that they will expand their partnership in ... bio-sensing cycling helmet and the first joint project between ... colors in order to give cyclists more style choices ... LifeBEAM and Lazer announced their plan to release a ...
(Date:4/21/2015)... 21, 2015 High crime ... are boosting access control systems market in ... a recently published report by TechSci Research " Saudi ... access control systems market in Saudi Arabia ... 2020.The access control systems market in the Kingdom is ...
(Date:4/14/2015)... Conn. , April 14, 2015 NXT-ID, ... a biometric authentication company focused on the growing mobile ... been nominated for the 2015 New York Design Awards ... The Design100, New York City Design Awards are part ... based on over 2,500 ratings from the marketplace, industry ...
Breaking Biology News(10 mins):LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 3Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 2Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 3NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3
(Date:5/22/2015)... 2015 Knowledgent , the data ... explores the potential of big data analytics in the ... developed to help life sciences and healthcare organizations understand ... gain critical business insights. , The life sciences and ... driven by patient profiling, compliance and regulatory requirements, and ...
(Date:5/21/2015)... Specialty Pharmacy Times has completed ... to BPA Worldwide as a business publication member. ... data for Specialty Pharmacy Times based on business/distribution, ... a member of BPA Worldwide, Specialty Pharmacy Times ... with the most reliable, unequaled data,” said Chris ...
(Date:5/21/2015)... May 21, 2015  The EveryLife Foundation for ... (R-UT) and Amy Klobuchar (D-MN) today ... Cures & Treatments, or OPEN ACT. ... advocacy organizations, this bipartisan legislation promises to rapidly ... to rare disease patients by incentivizing drug makers ...
(Date:5/21/2015)... , May 21, 2015  CytRx Corporation (NASDAQ: ... company specializing in oncology, today announced positive updated ... with aldoxorubicin for the treatment of unresectable glioblastoma ...  The open-label, multisite trial is designed to investigate ... patients whose tumors have progressed following prior treatment ...
Breaking Biology Technology:New White Paper Explores the Potential of Big Data Analytics in Life Sciences and Healthcare 2Specialty Pharmacy Times Joins BPA Worldwide 2Advocates Cheer Senate Leaders for Introducing Bipartisan Bill to Increase Number of Rare Disease Treatments 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7
Cached News: